Pritchett Edward L C, Marcello Stephen R
Department of Medicine, Division of Clinical Pharmacology, Duke University Medical Center, Durham, North Carolina, USA.
Card Electrophysiol Rev. 2003 Sep;7(3):215-9. doi: 10.1023/B:CEPR.0000012385.15778.d2.
Azimilide dihydrochloride (or azimilide) is a class III antiarrhythmic drug currently under investigation that has been tested in atrial fibrillation in four randomized, placebo-controlled clinical trials to assess efficacy and dose range. These investigational trials showed that doses of azimilide 100 and 125 mg once daily prolonged the time to symptomatic arrhythmia recurrence in patients with a history of symptomatic atrial fibrillation, atrial flutter or both. Doses of 75 mg or less were not useful in this indication. Safety of azimilide has been examined in several different types of studies. In a large randomized clinical trial of post-infarct patients, azimilide neither increased nor decreased mortality risk. In patients with supraventricular arrhythmias, the most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Infrequent cases of torsade de pointes and severe neutropenia were reported in patients taking azimilide. Azimilide is an investigational antiarrhythmic drug that has shown efficacy in patients with atrial fibrillation.
盐酸阿齐利特（或阿齐利特）是一种正在研究中的III类抗心律失常药物，已在四项随机、安慰剂对照的临床试验中用于心房颤动，以评估其疗效和剂量范围。这些研究性试验表明，对于有症状性心房颤动、心房扑动或两者病史的患者，每日一次服用100毫克和125毫克阿齐利特可延长有症状性心律失常复发的时间。75毫克或更低剂量在此适应症中无效。阿齐利特的安全性已在几种不同类型的研究中进行了检验。在一项针对心肌梗死后患者的大型随机临床试验中，阿齐利特既未增加也未降低死亡风险。在室上性心律失常患者中，服用阿齐利特的患者报告的最常见不良反应的频率与服用安慰剂的患者大致相同：头痛、乏力、感染、腹泻和头晕。服用阿齐利特的患者报告了罕见的尖端扭转型室速和严重中性粒细胞减少病例。阿齐利特是一种已在心房颤动患者中显示出疗效的研究性抗心律失常药物。
